Forest Labs files lawsuit to stop generic memantine

Generics/News | Posted 07/02/2014 post-comment0 Post your comment

Forest Laboratories and Forest Laboratories Holdings (Forest) announced on 31 January 2014 that the company has filed a lawsuit in the US against several generics makers for their generic versions of Forest’s blockbuster Alzheimer’s disease treatment Namenda XR (memantine).

Memantine V14B07

Forest has jointly filed a lawsuit, along with Merz Pharma (Merz) and Adamas Pharmaceuticals (Adamas), in the US District Court for the District of Delaware against several companies for infringement of US patents on Forest’s Namenda XR product. Forest licenses one patent (5,061,703), which expires in April 2015, from Merz, and six patents (’209, ’708, ’379, ’752, ’085 and ’233), which expire in November 2025, from Adamas. Forest also owns one patent on Namenda (’009), which expires in March 2029.

Namenda XR is a once-daily extended-release version of the company’s immediate release (IR) formulation of Namenda. Namenda XR is approved for the treatment of moderate to severe Alzheimer’s disease. Namenda IR is a top revenue earner for Forest Laboratories with fiscal year sales for 2013 of US$1.5 billion. However, the drug will lose patent protection and face generics competition from January 2015, hence the need to protect the extended-release version of the drug.

The generics makers named in the lawsuit include Sun Pharma Global, Teva Pharmaceuticals USA and Wockhardt Bio, all of whom have filed Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (FDA) seeking approval to market generics of Namenda XR before the expiration of some or all of the patents on the product.

In Europe, the patent on Namenda expired in August 2012 and generic memantine is already on the market in the European Union. The lawsuit in the US, however, means that FDA cannot approve the generic versions until June 2016 unless the court issues a decision against Forest, Merz and Adamas earlier.

Related article

Generics applications under review by EMA – 2013 Q4

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.

Source: EMA, Forest Laboratories

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010